Abstract: Congenital hypoparathyroidism caused by velo-cardio-facial syndrome (VCFS) typically presents with hypocalcemia in the neonatal period associated with other characteristic findings. We report the case of an 8-year-old boy presenting a hypocalcemic seizure (ionized calcium, 0.65 mM); he had a history of velopharyngeal insufficiency and late development with language impairment; at presentation, minor dysmorphic features were noticed. Laboratory evaluation revealed a parathormone level of < 1.0 pg/mL. VCFS was confirmed by fluorescence in situ hybridization study revealing the 22q11.2 deletion. High levels of calcium administration were needed to normalize serum calcium. In this case, signs of hypoparathyroidism only developed in late childhood, and the patient, despite the minor clinical signs of VCFS, remained symptom-free. He presented no cardiac malformations, immunologic abnormalities, or renal dysfunction often associated with this diagnosis. In a child with hypocalcemia, considering the hypothesis of VCFS, even if there are no other manifestations, is important both for clinical diagnosis and management and for genetic counseling.
Introduction
Hypoparathyroidism is a rare condition characterized by hypocalcemia caused by a decreased production of parathormone (PTH) or an insensitivity to its action (1) . There are several causes, such as complex syndromes (DiGeorge, Kearns-Sayre, and Sanjat-Sakati), PTH gene defects, calcium sensing receptor mutations, and isolated X-linked hypoparathyroidism (1) . In syndromic cases, the clinical aspects vary, but usually the first signs and symptoms of hypocalcemia develop in the neonatal period or in early childhood (1) .
Velo-cardio-facial syndrome (VCFS), also known as DiGeorge, has multiple phenotypic anomalies associated (2) . The reported incidence is approximately 1 per 4000 live births (2) . The first description, in 1968, reported a child with the triad hypoparathyroidism, thymic hypoplasia, and recurrent infections (2) . In 1978, the full spectrum of VCFS was described (2) . In 1980, the autosomal dominant pattern of inheritance was confirmed, and in 1992, the genetic mutation responsible for the vast majority of cases was identified: a microdeletion on chromosome 22q11.2 (2) . In a small number of patients, other mutations were identified (3) .
Most cases are sporadic, but familiar incidence is reported in 8 % to 15 % according to the series (4) .
We report a case of a boy who presented at age 8 years old with a first episode of seizure. He had mild facial dysmorphic features, nasal speech, and late development with language impairment. Laboratory evaluation revealed hypocalcemia caused by primary hypoparathyroidism, suggesting VCFS. Fluorescence in situ hybridization (FISH) study confirmed this diagnosis, revealing the deletion on chromosome 22q11.2 band.
This case of VCFS has a very unusual presentation because hypocalcemia developed only at age 8 years old, and despite some clinical facts, the diagnosis of VCFS remained unveiled. VCFS is therefore also a cause of hypocalcemia outside the neonatal period.
Case report
This 8-year-old Caucasian boy is the first child of a healthy unrelated, young couple. The mother, the father, and the grandfather had a history of language impairment; the maternal grandmother had epilepsy.
Pregnancy was uneventful, vaginal delivery occurred at 38 weeks, and Apgar index was 9 and 10 at 1 and 5 min, respectively. Birth weight [2960 g (10 -25th percentiles)], birth length [47 cm (10th percentile)], and head circumference [34 cm (10 -25th percentiles)] were normal. The neonatal period was uneventful.
He was followed for mild cognitive deficit, development and language impairment, attention-deficit hyperactivity disorder, and learning difficulties. He also had regular evaluations for strabismus and decreased visual acuity as well as decreased hearing acuity.
He thrived within the 25th percentile.
The boy presented to the emergency department 30 min after a first tonic-clonic generalized seizure that had stopped spontaneously after 5 min. At arrival he was sleepy, with amnesia for the episode. He was bradycardic and normotensive. The physical examination revealed a triangular facies, mild projection of the upper jaw, protruding and apart upper teeth, hands and feet with mild fetal pads, and nasal speech ( Figure 1 ). There were not any focal neurologic signs. The electrocardiogram showed bradycardia (55 -65 ppm), long QT interval, and extrasystoles; the echocardiogram was normal.
Biochemical evaluation revealed severe hypocalcemia [serum ionized calcium, 0.65; reference values (RV), 1.15 -1.32 mM; serum total calcium, 5.1; RV, 8.7 -10.2 mg/dL], raised serum phosphate (7.7 mg/dL), and normal serum alkaline phosphatase (123; RV, < 500 U/L), total protein (7.3; RV, 6.3 -8.1 g/dL), and albumin (4.8; RV, 3.8 -5.4 g/dL). PTH levels were undetectable ( < 1; RV, 12 -65 pg/mL; 25-hydroxyvitamin D levels were normal (27.3; RV, 11 -70 ng/mL).
In view of hypoparathyroidism associated with mild dysmorphic features, developmental delay, and nasal speech, the hypothesis of VCFS was raised.
Cervical ultrasound and magnetic resonance imaging showed a normal thyroid but no thymus remnant or parathyroid glands. Standard chromosome analysis showed a normal male karyotype (46, XY). The FISH study revealed a microdeletion on chromosome 22 on the q11.2 band, confirming the clinical hypothesis of VCFS. A further evaluation to elucidate other clinical characteristics of VCFS was carried out: normal levels of IgM (1.74; RV, 0.55 -1.6 g/L), IgG (12.7; RV, 7.6 -13.3 g/L), IgA (2.09; RV, 1.08 -2.00 g/L), and lymphocyte populations were found.
A genetic study of the mother was carried out and found to be negative for the 22q11.2 microdeletion. The father was not available for study.
The correction of hypocalcemia was very difficult. At the beginning, high doses of intravenous calcium gluconate were needed; intravenous infusion was progressively reduced and the oral intake proportionally increased and oral calcitriol was associated (0.75 mg/day).
The child could be discharged after 48 days of hospitalization. Total serum calcium, ionized serum calcium, and serum phosphate were within the normal range; PTH levels remained undetectable. He was treated with 1 g calcium carbonate per os twice daily and calcitriol as above.
He has been followed up in our outpatient clinic, with regular clinical and laboratory evaluations. Therapy with oral calcium carbonate and calcitriol has been adjusted according to the needs. Three years later, he remains seizure-free, growing well along the 25th centile.
Discussion
Hypocalcemia is defined by low serum ionized or total calcium after correction for the albumin concentration. Several mechanisms can cause it, such as inadequate PTH secretion or insensitivity to its action, abnormal magnesium metabolism, insufficient vitamin D intake or decreased activity of its receptor, or in clinical situations in which several factors are combined (e.g., sepsis and pancreatitis) (1) . In our case, hypocalcemia was secondary to primary hypoparathyroidism.
Hypocalcemia has a broad spectrum of clinical presentations depending on its duration, severity, and speed of installation. Neuromuscular symptoms and signs are the most frequent manifestations presenting as muscle cramps, fasciculations, spasms, paresthesia, laryngospasm, or bronchospasm. Hypocalcemia can also present as an emergent situation, such as stridor, tetany, seizures, impaired conscience, or refractory heart failure (1) .
Primary hypoparathyroidism causes hypocalcemia because PTH secretion is insufficient to mobilize calcium from bone, stimulate its reabsorption at the distal nephron, and promote the renal 1 α -hydroxylation of 25-hydroxyvitamin D to its biologically active form (1,25-dihydroxyvitamin D), necessary to the intestinal absorption of calcium. From a biochemical point of view, it is characterized by hypocalcemia, hyperphosphatemia, and inappropriately low or even undetectable levels of PTH (5) .
In our patient, the coexistence of hypocalcemia secondary to hypoparathyroidism, minor facial dysmorphism, nasal voice, and impaired speech and development raised the suspicion of VCFS despite the absence of previous symptoms. The diagnosis was confirmed by FISH study that showed the characteristic 22q11.2 deletion syndrome.
Most cases of VCFS are sporadic, although some familial cases have been described (4) . In the reported case, the maternal karyotyping was normal, with no 22q11.2 deletion. A paternal mutation could not be excluded.
There are no pathognomonic or required phenotypic characteristics of VCFS; therefore, the diagnosis depends on a high index of suspicion (2) . The clinical spectrum is variable and results of a combination of more than 180 phenotypic characteristics. Some of the most frequent manifestations were present in our patient: learning disabilities and speech impairment (70 -90 % ), velopharyngeal insufficiency (69 % ), parathyroid dysfunction (60 % ), and facial dysmorphism (70 % ). The other common and more well-known features are conotruncal cardiac malformations (74 % ), primary immunodeficiency (80 % ), and renal malformations (36 % ), which were not present in our patient (4) .
Diagnosis is confirmed by finding the characteristic microdeletions on the q11.2 band of chromosome 22 by FISH study.
In the great majority of cases, the hypothesis of VCFS is raised during the neonatal period or early childhood in the context of the etiologic study of cardiac malformation, hypocalcemia, and/or facial dysmorphism (2) .
The hypoparathyroidism associated with VCFS usually appears during the neonatal period (6) . The cases associated with hypocalcemic seizures are rare, even in the largest series (4) , and arise either in neonatal period and infancy or during adolescence, which are periods of increased needs of calcium. Hi é ronimus et al. and Tsai et al. described three cases of women with seizures since childhood/teenage years, with poor response to antiepileptic drugs. A thorough etiologic study showed that the clinical manifestations in these patients were a consequence of hypocalcemia secondary to hypoparathyroidism in the context of VCFS (6) . To our knowledge, this is the first reported case in late childhood.
The patient was treated with oral calcium bicarbonate and calcitriol as usual; normocalcemia was difficult to achieve, needing high levels of calcium administration.
There are a few reports of good results with the therapy with PTH, but this therapy is not yet approved (1) .
Conclusion
We report a case of an 8-year-old boy with a first seizure, whose etiologic investigation led to the diagnosis of VCFS. We want to draw the attention to this diagnostic hypothesis, even after the neonatal period, particularly in children or adolescents with hypoparathyroidism, facial dysmorphism, and developmental and language delay, despite the absence of features frequently associated with the syndrome such as cardiac malformations and immunologic deficiency.
